Light Mode
$2.80 ↑ +0.00 (+0.00%) Trading Up from the previous close of $2.80
-5.26 (-65.26%) / 6M
Momentum, market sentiment, and recent alerts
BBOT reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is -75.8%.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
Bridgebio Oncology Therapeutics, Inc. engages in developing bioavailable small molecule inhibitors. It focuses on advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. The company was founded on August 1, 2016 and is headquartered in South San Francisco, CA.
No peer group available for this symbol.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.